Skip to main content
Biocon Ltd. logo

Biocon Ltd. — Investor Relations & Filings

Ticker · BIOCON ISIN · INE376G01013 LEI · 335800NK3L7QCHLOC198 BSE.NS Manufacturing
Open in API
Filings indexed 1,691 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS BIOCON

About Biocon Ltd.

https://www.biocon.com/

Biocon Ltd. is a global biopharmaceutical company focused on developing innovative therapies for chronic conditions such as diabetes, oncology, and autoimmune diseases. The company specializes in the research, development, and manufacture of high-quality biosimilars, generic active pharmaceutical ingredients (APIs), and novel biologics. Its portfolio includes recombinant human insulin, insulin analogs, and monoclonal antibodies. Biocon leverages an integrated business model encompassing advanced research and development, large-scale manufacturing, and global commercialization. By prioritizing affordable innovation, the company aims to enhance access to life-saving treatments across international markets, including the United States, Europe, and emerging economies. Its technical expertise in microbial fermentation and complex protein engineering supports a robust pipeline of complex therapeutics designed to address unmet medical needs.

Recent filings

Filing Released Lang Actions
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Regulatory Filings Classification · 82% confidence The document is a notice sent to stock exchanges under SEBI Listing Regulations informing about the schedule of management meetings with analysts/institutional investors. It does not contain slides or substantive financial results, nor is it an AGM presentation, earnings release, or a transcript. It’s a compliance disclosure with no substantive report attached and thus falls under general Regulatory Filings.
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a routine stock exchange disclosure under SEBI Listing Regulations, notifying the schedule of meetings with analysts/institutional investors. It does not contain financial results, presentations, or actual reports—it is a regulatory compliance announcement. This fits the catch‐all “Regulatory Filings” category (RNS).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 92% confidence The document is clearly the full text transcript of Biocon Limited’s Q4 FY26 earnings conference call, including prepared remarks, speaker lists, and Q&A format. It is not just an earnings release summary or investor presentation, but the verbatim call transcript, which matches the definition of a Call Transcript (CT).
2026-05-14 English
Transcript of Earnings Call Q4 FY 26
Call Transcript Classification · 95% confidence The document is headed “Transcript of Earnings Call Q4 FY26,” contains a letter to stock exchanges enclosing the full transcript, and includes speaker lists, prepared remarks, and Q&A from the earnings conference call. This clearly matches the definition of a full call transcript of a company conference call. Therefore, the appropriate classification is CT.
2026-05-14 English
Company Statement
Regulatory Filings Classification · 62% confidence The document is a Company Statement addressed to BSE and NSE announcing Health Canada approval for a product. It is a generic stock exchange notification of corporate news rather than a financial report, board change, dividend, or other specific category. Such miscellaneous regulatory announcements are classified as Regulatory Filings (RNS).
2026-05-11 English
Updates
Regulatory Filings Classification · 10% confidence The document is a notification sent by Biocon Limited to the stock exchanges (BSE/NSE) announcing Health Canada’s approval for a pharmaceutical product. It is a corporate announcement to satisfy listing regulations and does not contain financial statements, voting information, or details of a formal report or presentation. It falls under general regulatory disclosures – a Regulatory Filing.
2026-05-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.